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Purpose. The aim of the present study was to assess whether two widely used biomarkers for 5-HT1A-
receptor mediated responses in the rat (hypothermia and corticosterone increase) could be scaled to
man using allometric principles.
Materials and Methods. Mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) models were
developed and characterized in rats for the standard 5-HT1A-receptor agonists, buspirone and
flesinoxan. Allometric scaling was investigated on the basis of simulation taking into account the
inter-individual variability and clinical study design. The model-predicted effects of both flesinoxan and
buspirone were compared to those published in the literature.
Results. The main finding of this analysis was that for both hypothermia and cortisol increase, the model
could predict the extent of the pharmacological response in man adequately. For the hypothermic
response, the time course of the response was also predicted with a high degree of accuracy. In contrast,
in the case of the cortisol response, the observed time lag was, despite the fact that it fell within the
model uncertainty, not predicted.
Conclusions. Based on these analyses, it is concluded that allometrically scaled mechanism based PK–
PD models are promising as a means of predicting the pharmacodynamic responses in man. This
approach provides for a novel way of interpreting and scaling pre-clinical pharmacological responses and
ultimately facilitates the understanding and prediction of pharmacological responses in man.
KEY WORDS: allometric scaling; corticosterone; cortisol; hypothermia;
pharmacokinetic–pharmacodynamic modeling; 5-HT1A receptors.
INTRODUCTION
Allometric scaling has been successfully applied to
predict a variety of biological rates, times and dimensions
(including metabolic rate, lifespan, growth rate, heart rate,
DNA nucleotide substitution rates and length of aortas)
between species of several orders of magnitude in body
weight (for reviews see 1–3). In particular, drug metabolism
is an area where methods based on allometric scaling
principles have become a basis for the scaling preclinical of
pharmacokinetic (PK) models to predict the time course of
drug concentrations in man (4,5). It has been hypothesized
(6–8) that similar methods may also be used to scale
integrated pharmacokinetic–pharmacodynamic (PK–PD)
models between species to predict time course of drug effects
in man. However, currently there is very limited evidence
that this is indeed the case. The premise for the cross-species
scalability of PK–PD models is based on two fundamental
assumptions, namely that (1) the model describes an essential
part of the physiology of the system studied and (2) both the
drug–receptor interaction and the physiological control
systems are similar across the species studied. Recent work
by Lepist and Jusko (7) has shown that using a relatively
simple physiological model it was possible to scale both PK
and PD parameters across four species. The aim of the
present report was to explore the allometric scaling of the
hypothermic response and the increase in corticosterone
following the administration of 5-HT1A receptor agonists
using two previously developed mechanism-based PK–PD
models (9).
Model predictions for the hypothermic and cortisol
response of the standard agents, flesinoxan and buspirone,
were compared to published data. It is anticipated that the
preliminary analyses presented in this study will aid the
further development of allometrically scaled mechanistic
PK–PD models which can be used to predict pharmacody-
namic response in man. Overall, we believe that this
approach provides a novel way of interpreting pre-clinical
pharmacological responses which will ultimately facilitate the
understanding of pharmacological responses in man.
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MATERIALS AND METHODS
In vivo Pharmacological Experiments. The details of the
pharmacokinetic–pharmacodynamic experiments in rats have
been described previously (10,11). Briefly, 8 days prior to the
experiment, the rats were operated upon. Indwelling cannu-
las for drug administration and blood sampling were
implanted into the right jugular vein and the left femoral
artery respectively. Furthermore, a telemetric transmitter
(Physiotel implant TA10TA-F40 system, Data Sciences
international (DSI), St. Paul MN, USA), was implanted into
the abdominal cavity for the measurement of core body
temperature. In the PK–PD experiments, conscious freely
moving rats received an i.v. infusion of vehicle (saline) or
active drug. Flesinoxan was administered in 3 mg/kg in 5 min
(n=6), 10 mg/kg in 5 and in 15 min (both n=6) infusions.
Buspirone was administered in a 5 mg/kg in 15 min (n=6) and
a 15 mg/kg in 15 min (n=7) infusion. In each experiment in
each individual rat approximately 15 to 18 serial blood
samples of 50 ml were taken according to a fixed time schedule
to determine the time course of the drug and corticosterone
(for flesinoxan only) concentration. Body temperature was
measured continuously throughout the experiment using the
telemetric system. All procedures were conducted in compli-
ance with national legislation and were ethically reviewed.
Human Data. The time courses of the pharmacodynam-
ic responses in humans, used for comparison were taken from
various publications (Table I and Fig. 1). The publications
were selected because they contained a time-course of either
the hypothermic or the corticosterone response to flesinoxan
or buspirone. The different studies varied in design, and
included open-label and cross-over studies as well as double
blind and parallel run studies. The mean temperature and
corticosterone versus time profiles were taken from the
selected publication and were used for comparing the
simulation results. Where the baseline temperature was not
available a weighted average (36.51-C) was used as a
substitute. Since few papers reported the actual body weight
of the subjects, often healthy volunteers, a body weight of 70
kg was assumed. This is considered a reasonable assumption
since the average body weight of the subjects in the studies
reported by Seletti et al. (12) and Pitchot et al., (13) were 73.2
and 73.8 kg, respectively.
The buspirone doses in the studies available in humans
were administered orally; whereas the doses tested in the rats
were given intravenously. Therefore, in the simulations
buspirone was administered as a 50 min infusion to represent
an oral dose which reaches a Cmax at 0.8 h and the 30 mg
dose was multiplied by a factor of 0.04 to reflect the absolute
bioavailability of 4% (14).
Mechanism-based PK–PD Models. The pharmacokinet-
ic and pharmacodynamic models and their analyses have
been published previously (9–11). Briefly 2- and 3-compart-
ment pharmacokinetic models were used for the pharmaco-
kinetics of buspirone and flesinoxan, respectively. The
pharmacokinetic profiles were used to quantify the relation-
ship between the time profile of the agonist blood concen-
tration and the time course of the hypothermic and
corticosterone response. For this purpose, the previously
described mechanistic PK–PD model (9) was fitted to the
data on the time course of the hypothermic effect for each
individual rat. In this model the hypothermic effect by the 5-
HT1A-receptor agonists is considered to be the result of the
attenuation of a set-point control by the drug receptor
interaction. The model takes into account a zeroth order
rate constant associated with the warming of the body (kin)
and a first-order rate constant associated with the cooling of
the body (kout). The thermostat-like regulation is implement-
ed as a continuous process in which body temperature (T) is
compared with a fixed reference or set-point temperature
(TSP). 5-HT1A agonists elicit hypothermia by decreasing the
baseline set-point value (T0);
TSP ¼ T0  1  f Cð Þ½ ; ð1Þ
whereby the extent of the decrease is a function of the drug
concentration C via the sigmoidal Emax-model.




where, Emax represents the maximum stimulus the drug can
produce, EC50 is the drug concentration required to produce
50% of the maximum stimulus and nH is a slope factor, which
determines the steepness of the curve. This yields the
following system of equations:
dT
dt
¼ kin  kout  T  X;
dX
dt







in which X denotes the thermostat signal, which is driven by
the difference between the body temperature T and the set-
point temperature TSP on a time-scale governed by the rate
constant a in Eq. 3. The thermostat signal affects the cooling
of the body through an effector function X , which
multiplies the first order rate constant kout. With four system
Table I. Summary of the Literature Data Used for the Hypothermic and Cortisol Effect of Buspirone (Just Temperature) and Flesinoxan in
Humans
Nr Reference Drug Response Doses n
1 Anderson & Cowen, 1992 (21) Buspirone T 30 mg, oral 10
2 Young et al., 1993 (19) Buspirone T 0 & 30 mg, oral 8
3 Blier et al., 2002 (22) Buspirone T 30 mg, oral 12
4 McAllister-Williams & Massey, 2003 (20) Buspirone T 0 & 30 mg, oral 14
5 Seletti et al., 1995 (12) Flesinoxan T/C 0, 7 & 14 mg/kg, i.v. 11
6 Pitchot et al., 2002 (13) Flesinoxan T/C 0, 0.5 & 1 mg, i.v. 12
T represents temperature and C cortisol in the response column.
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parameters to be estimated, the degree of parameterization
in Eq. 3 is high and this may lead to parameter identifiability
problems. It has been shown that one parameter can be
eliminated in a procedure involving the introduction of
dimensionless variables (9). The procedure results in the
establishment of the parameters A and B defined by,












where T0 and X0 are the values for T and X when no drug is
present. Note that A and B represent the relative growth rate
of, respectively X and T when C=0 and T=T0.
The plasma corticosterone concentration-time profiles
were described by an indirect physiological response model (10);
d Cort½ 
dt
¼ kin  f Cð Þ  kout  Cort½ ; ð5Þ
where [Cort] represents the corticosterone concentration, f(C)
a sigmoidal Emax-model (Eq. 1), kin is a zeroth order rate
constant associated with the production of corticosterone and
kout a first-order rate constant associated with the elimination
of corticosterone. The pharmacokinetic and pharmacodynamic
parameters are given in Table II.
Allometric Scaling of the Pharmacokinetic
and Pharmacodynamic Parameters
The scaling of the physiological parameters and rate
constants involves extrapolating parameters based on body
weight (BW) following a simple power law, given by
Y ¼ p  BWb; ð6Þ
where the exponent (b) generally assumes multiples of 1/4. Y
is the parameter of interest and p the weight independent
parameter (15). Typically b assumes the value of j1/4 for
first order rate constants and the value of 3/4 for zeroth order
constants (2,15). The rat pharmacokinetic parameters, clear-
ance and volume, and the rat pharmacodynamic parameters,
the first order rate constants, kout and A were scaled to
obtain human parameters based on weight using the expo-
nent, b equal to 3/4, 1 and j1/4, respectively (2,15)
The drug-related parameters potency, intrinsic activity,
slope were not transformed because it is believed that affinity
and efficacy are tissue and receptor dependent, both of which
are expected to be similar in man and rat for the 5-HT1A
receptor (89% receptor homology) (16). However, parame-
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Fig. 1. The temperature and cortisol responses over time for buspirone and flesinoxan in the references mentioned (Table I). Note that the
lower two right panels depict cortisol data whereas the rest depicts temperature data. The numbers in the graphs represent the different doses
used, where 1 represents the placebo or lowest dose used and 2 and 3 the next dose levels—please see Table I for the actual doses.
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reflect the true concentration at the site of actions. It is
therefore proposed to use information from receptor binding
and functional assays to supplement this information.
In a meta-analysis of various 5-HT1A receptor agonist
effects on hypothermia, Zuideveld et al. (17) have shown that
the affinity of flesinoxan is underestimated by approximately a
factor 30. The underestimation is likely to be due to the fact that
flesinoxan is subject to an active transport mechanism, resulting
in a drug receptor association rate constant (Ka), estimate based
on blood concentrations which may not be representative of the
concentration at the site of the 5-HT1A receptor (18). The
potency of flesinoxan was therefore scaled up 30 fold.
The amplification factor g, the inter-individual variabil-
ity and the residual error (proportional) were not scaled since
they are dimensionless. It is acknowledged that variability
may not directly translate across species. Since the PD
parameters are determined in a population of Wistar rats,
which may be considered less heterogeneous than the human
population, this may result in an underestimation of inter-
individual variability.
For the body weight of the rats a value of 0.3 kg (true
body weight was 0.297T0.0034 kg, mean T SEM) was used.
The scaled and non-scaled pharmacokinetic and pharmaco-
dynamic parameters are represented in Table II.
The accuracy of the allometrically scaled pharmacoki-
netics was assessed by comparison with values reported in
literature. Since the pharmacokinetic parameter obtained in
the literature have been obtained using different models (1-
versus 2- or 2- versus 3-compartmental models) and different
estimation techniques (non-compartmental analysis versus
non-linear mixed effects modeling) only the values of the
Clearance (Cl), Volume of distribution at steady state, and
terminal elimination half life can be reliably compared.
Simulations
Both mechanism-based PK–PD models were implemented
in the clinical trial simulation software, Trial Simulator (v2.1.2,
Pharsight Corporation, Mountain View, CA) and are available
upon request. The designs of the studies mentioned was
replicated as much as possible, taking into account the route
of administration, the dose and the number of patients. Each
study was replicated 1,000 times. The population PK–PD
parameters were sampled from a multivariate normal distribu-
tion at study level, the individual parameter estimates were
based on these new population parameters and a random
sample from the distribution characterized by the inter-
individual variability. Once sampled the parameters were scaled
Table II. Overview of the Pharmacokinetic and Pharmacodynamic Parameters Estimates for Buspirone and Flesinoxan in Rats (11,12) as
Well as the Scaling Parameter, b Used in Eq. 4 and the Resulting Parameter for Humans
Drug Type Parameter Rat value IIV (%) b Human value Unit
Flesinoxan PK Cl 2.96 51 0.75 176 ml/min
Cl2 0.827 59 0.75 49.4 ml/min
Cl3 48.1 39 0.75 2,870 ml/min
V1 10.2 70 1 2,380 ml
V2 226 61 1 52,700 ml
V3 347 30 1 81,000 ml
Res. err. 23 n.s. 23 %
Hypothermia kin 2.23 49 j0.25 0.571 -C/min
A 0.0167 76 j0.25 0.00427 minj1
g 6.42 87 n.s. 6.42 n.a.
EC50 714 33 Factor 30
* 23.8 ng/ml
nH 1.84 63 n.s. 1.84 n.a.
Emax 0.705 43 n.s. 0.705 n.a.
Res.err. 11 n.s. 11 %
Cortico./Cortisol kout 0.151 <1 j0.25 0.0386 min
j1
EC50 462 <1 Factor 30
* 15.4 ng/ml
nH 2.34 126 n.s. 2.34 n.a.
Emax 1.58 342 n.s. 1.58 n.a.
Res.Err 42 n.s. 42 %
Buspirone PK Cl 17.6 51 0.75 1050 ml/min
Cl2 41.7 35 0.75 2490 ml/min
V1 8.94 96 1 2090 ml
V2 626 38 1 146000 ml
Res. err. 28 n.s. 28 %
Hypothermia kin 1.24 44 j0.25 0.317 -C/min
A 0.0201 26 j0.25 0.00514 minj1
g 5.87 10 n.s. 5.87 n.a.
EC50 17.6 79 n.s. 17.6 ng/ml
nH 0.89 61 n.s. 0.89 n.a.
Emax 0.465 19 n.s. 0.465 n.a.
Res. err. 9 n.s. 9 %
Drug specific parameters, the inter-individual variability (IIV) and the residual error (Res. Err.) were not scaled (n.s.). In the simulation
routine individual parameter are drawn using the population parameter estimate and the inter-individual variability and then scaled.
* See explanation in the methods section
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to a value for humans. On each measurement a proportional
random error was added. Following each replicate the mean
time profile, the maximal decrease (Rmax) and the slope of the
decrease (Rate) for each dose-arm were calculated using S-
PLUS (v6.1, Insightful Corporation, Seattle, WA). These values
were then compared to observed values, allowing for assess-
ment of the simulation performance. The 90% prediction
intervals were calculated after simulation of 1,000 replicates
and represent the fifth and 95th quantile.
RESULTS
Underlying the PD predictions are the allometrically
scaled PK parameters. Although it is not the intent of this
manuscript to address allometric scaling of PK parameters,
grave errors in the PK predictions can be expected to carry
through in the PD predictions. The scaling of the pharmaco-
kinetic parameters of flesinoxan (10) and buspirone (11)
resulted in estimates of the clearance of 176 and 1,050 ml/min
and of the volume of distribution at steady state (Vss) of 136
and 148 L for a Ftypical_ human weighing 70 kg respectively.
Bachman et al. (23) and Mahmood et al. (14) have reported a
clearance of 163 and 1,980 ml/min and a Vss of 66 and 371 L
for flesinoxan and buspirone respectively (see Table III for
details). Although the parameters were obtained using
different methods, within the context of allometric scaling
the PK predictions for felsinoxan and buspirone are consid-
ered adequate.
Using the allometrically scaled PK and PD parameters
determined in rat, generic median predicted time course
following 5 mg in a 15 min i.v. infusions of either busprione
or flesinoxan for the hypothermic and the corticosterone/
cortisol response respectively in man were simulated and are
depicted in Fig. 2. The shaded regions denote the simulated
90% confidence interval based on the simulation of 100
subjects, thereby taking into account inter-individual vari-
ability, residual error (proportional) and parameter uncer-
tainty. Both for the hypothermic response and for the cortisol
response markedly different time-courses were predicted.
Using the specific study designs, with respect to dose,
number of patients, and sampling points described by the
different references (Table I) the time courses of the
hypothermic and, where possible, the cortisol responses were
simulated. Fig. 3 depicts the simulated 90th percentile
prediction intervals for the hypothermic responses in humans
for buspirone and flesinoxan (top 2 rows of 4) and the
simulated cortisol response for flesinoxan (hashed areas) by
study and dose. The observed hypothermic and cortisol
response is denoted by the filled circles and connecting line.
Overall, the time course of both responses was captured well
for both drugs. Only for the high dose in the cortisol response
described by Seletti et al. (12) and the low dose in the study
described by Pitchot et al. (13) the predictions were near the
upper and lower end of the prediction interval. Following
each trial replicate the maximal response (Rmax) and the
Rate of reaching this maximal response was characterized in
order to capture the shape of the time course numerically.
This was compared to the same metric calculated from the
observed data (Table IV). The maximal response was
expressed as absolute value relative to the baseline (hypo-
thermia) or as absolute value relative to placebo response
(Cortisol). The predicted value represents the median
prediction over 1,000 simulations and the fifth and 95th
percentile represent the 90% prediction interval (90% P.I.).
Overall, the time course of both responses was predicted well
for both drugs, when comparing the maximal decrease
(Rmax) and the Rate of decrease. Interestingly, the placebo
response for the hypothermic effect in the buspirone studies
was predicted poorly. Both the Rmax and the Rate were
predicted to be essentially zero as no response was expected
when zero drug is administered. In the studies reported by
Young et al. (19) and McAllister-Williams and Massay, (20),
however, a decrease in core body temperature was observed
for the placebo response which explains this poor prediction.
Conversely, no such placebo response was observed in the
studies conducted by Seletti et al. (12) and Pitchot et al. (13).
For the cortisol response the rate of the increase was
respectively under and over predicted for the high and the
low dose of the studies reported by Seletti et al, and Pitchot et
al. Close inspection of Fig. 3 indicates a certain lag time
before the cortisol response fully develops—a similar delay in
the corticosterone response was not observed in rats.
DISCUSSION
We have shown that two preclinical mechanism-based
PK–PD models, one for the hypothermic and one for the
corticosterone response to 5-HT1A receptor agonist, can be
scaled with some degree of success to man using allometric
principles (Fig. 3 and Table IV). Allometric scaling of the
physiological parameters of the set-point model and the
direct use of the drug related parameters as well as their
variability has shown that the hypothermic response to
buspirone and flesinoxan can be predicted adequately both
Table III. Overview of the Predicted Pharmacokinetic Parameters Clearance (Cl), Volume of Distribution at Steady State (Vss) and
Terminal Elimination Half-life (t1/2) in Humans Compared to Published Observed Pharmacokinetic Parameters in Humans for Flesinoxan
and Buspirone (14,23)
Drug Parameter Predicted value Rat IIV (%) Observed value Observed IIV (%) Unit
Flesinoxan Cl 176 51 163 20 ml/min
Vss 136,080 66,200 ml
t1/2 536 282 min
Buspirone Cl 1,050 51 1,980 ml/min
Vss 148,090 371,000 ml
t1/2 98 150 min
Where necessary the Vss and the terminal elimination half-life (t1/2) have been derived and represented in italics; where Vss equals the sum of
all Volumes and t1/2= (ln2*Vss)/Cl.
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with respect to the extent as well as the time course of the
response. Allometric scaling of the corticosterone response of
flesinoxan has been successful only with respect to the extent
of the cortisol response. However, the time course of the
cortisol response was not adequately predicted. The observed
lag in the pharmacological response was not adequately
explained by the indirect physiological model. The observed
lag-time in humans may be explained by a control system
(e.g. via hypothalamic–pituitary–adrenal axis) which is not
captured by the indirect-physiological response model. It is of
interest to note that this lag has not been observed in the rats.
Following allometric principles, it can be speculated that the
corticosterone response in rats is subject to a delay of less
than 15 min. Unfortunately, the frequency of sampling of the
corticosterone response in Zuideveld et al. (10) (at times 0,
10, 25, 40 min, etc.) did not allow for such a lag to be
detected.
It is our view that the main reasons why the present
scaling of the two mechanism-based PD models has been
partly successful are that 1) the models were developed on
the basis of the underlying physiology of the system under
investigation and 2) that both the drug–receptor interaction
and the physiological control systems are similar across the
species studied. In this respect it is of interest to note that
both for the hypothermic and the cortisol response, allome-
tric scaling predicts that for humans the rate of the onset of
the response is lower (reaching a maximal effect at a later
time) and returns to baseline earlier (Fig. 2). In addition, the
oscillatory time course of the hypothermic response in rats
virtually disappears in a human which concurs with the
observed clinical profiles.
The dependency of oscillatory time courses on body
weight is inherent to the system. The oscillatory behavior
depends on the values of the parameters in the system;
scaling for larger body weights—using multiples of 1/4—
results in values which do not show these typical oscillations.
Allometric scaling of body temperature has often been
related to allometric scaling of basal metabolic rate, which
in turn has been argued to scale better with multiples of 1/3
(24). An exponent of 2/3 was first proposed by Rubner in
1883 (25) for basal metabolic rate and is in accordance with
simple geometric and physiological principles if loss of
temperature is assumed to be solely dependent on body
surface area. In a recent paper by Chaui-Berlinck et al. (26) it
is argued that whilst physical and geometrical principles are
important, parameters which fall under the rein of control








































































Fig. 2. The median predicted temperature–time (a) and cortisol–time (b) profile for a human (solid white line) based on allometrically scaled
parameters determined in a rat (solid black line). The shaded regions denote the simulated 90% confidence interval based on the simulation of
100 subjects (gray: humans, hashed: rats), thereby taking inter-individual variability, residual error and parameter uncertainty into account. In
the example 5 mg is administered in a 15 min i.v. infusions of either busprione of flesinoxan for the hypothermic and the corticosterone/
cortisol response respectively (i.e. the buspirone parameters are used for the temperature simulations and flesinoxan ones for the
corticosterone/cortisol simulation). See Table II for the rats and scaled-human parameters.
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systems fall outside the realm of these principles. In their
paper, Chaui-Berlinck et al. (26) propose a similar control
system for the control of body temperature as the one in Eq.
1. Using allometric scaling Chaui-Berlinck et al. (26) hypoth-
esize oscillations in the temperature adjustments of small
homeoterms versus a graded response in large homeoterms.
The current investigation therefore provides experimental
evidence to this argument.
The drug related parameters Emax, EC50, nH and
amplification factor g, have not been scaled since generally
serotonergic and other aminergic G-protein-coupled-receptor
systems are considered to be fairly similar across both species
(16). However, flesinoxan_s EC50 required adjustment in
order to adequately predict the hypothermic and cortisol
response in man. In this respect it is important to note that in
a meta-analysis of various 5-HT1A receptor agonist effects on
hypothermia Zuideveld et al. (17) have shown that the
affinity of flesinoxan is underestimated by approximately a
factor 30. This apparent inconsistency can be explained by
either a large difference in receptor reserve or a dispropor-
tionate difference in flesinoxan blood and effect site concen-
tration. We believe that the latter explanation is the most
likely. Specifically, a difference in receptor reserve would be
expected to be consistent for both buspirone and flesinoxan.
Conversely the predictions were consistently off for
flesioxan_s hypothermic and cortisol response, but not for
buspirone_s. Moreover, the notion that the EC50 determined
in blood might not adequately reflect the EC50 at the effect
site is supported by experiments showing that flesinoxan is
subject to active transport mechanism at the level of the
blood brain barrier (18). Although Van der Sandt et al. (18)
have observed a mere 7–10 fold difference in total blood:-
brain ration between wild type and MDR 1a (j/j) mice, it is
believed that differences in species, and methods used
account for the differences. Therefore, based on the under-
estimation of flesinoxan_s affinity in vivo by a factor 30 (17),
the EC50 was adjusted accordingly. In addition to the scaling
of the drug related parameters, the observed inter-individual
variability on the parameters has been assumed to be similar
across species. It is acknowledged that this assumption may
be conservative, since the PD parameters were determined in
a fairly homogeneous population of Wistar rats, with possibly
a lower inter-individual variability.
In the simulations the designs of the referenced studies
were imitated as much as possible, taking into account the
route of administration, the dose and the number of patients.
The population parameters were sampled from a multivariate
normal distribution at the study level and the individual
parameters were based on these new population parameters
and a random sample from the distribution characterized by
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Fig. 3. Simulated 90th percentile prediction intervals for the hypothermic responses in humans for buspirone and flesinoxan (top 2 rows of 4)
and the simulated cortisol response for flesinoxan (hashed areas) by study and dose (only the active doses are depicted & the title of each
graph denotes refers to the applied study design). The observed hypothermic and cortisol response is denoted by the filled circles and
connecting line. Note that the cortisol response has been corrected for the placebo response.
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the inter-individual variability. Further on each measurement
a random error was added in an attempt to adequately reflect
the range of possible profiles. In scaling the pharmacody-
namic parameters however a point estimate of the body
weight was used—whereas a distribution might more ade-
quately reflect the range of possible parameters. However
since little was known about the range of bodyweights in the
trials evaluated, although conservative, the use of a singe
number (70 kg) was considered more appropriate.
Despite the fact that the allometric predictions rely on a
number of assumptions, it is our anticipation that based on
these preliminary analyses, allometrically scaled mechanistic
PK–PD models could be used more widely to predict the
pharmacodynamic response in man. In addition it is believed
that in particular physiological systems which are conserved
from an evolutionary perspective would make good candi-
dates for allometric scaling of drug effects. The approach
presented provides for a novel way of interpreting pharma-
cological responses in a pre-clinical setting and should
ultimately facilitate the understanding of pharmacological
responses in man.
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